Bristol-Myers Squibb Co (NYSE:BMY) (Trend Analysis) shares were traded with thin volume. The stock closed last trading session at $71.53, up by 0.27%, with a volume of 5,758,820 shares against an average amount for the last three months of 6,115,970.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Bristol-Myers Squibb Co (NYSE:BMY) stock is currently trading 2.09% below its 52-week-high, 38.04% above its 52-week-low. The 1-year stock price history is in the range of $51.82 – $73.06. Bristol-Myers Squibb Co (BMY) has a price to earnings ratio of 76.91 versus Healthcare sector average of 40.79. BMY stock price has outperformed the S&P 500 by 1.8%. The Medical Drugs company is currently valued at $119.42 billion, and its share price closed the last trading session at $71.53. The stock has a 50-day moving average of $67.91 and a 200-day moving average of $65.81.
Bristol-Myers Squibb Co (BMY) current short interest stands at 21.5 million shares. It has decreased by 3% from the same period of last month. Around 21% of the company’s shares, which are float, are short sold. With a 10-days average volume of 6.04 million shares, the number of days required to cover the short positions stand at 3.6 days.
BMY is forecasted to report earnings per share of $0.64 and a revenue of $4.56 billion for the 2nd Quarter of the fiscal year 2016. Bristol-Myers Squibb Co (BMY) declared last quarter earnings on April 28. The Medical Drugs company announced last quarter earnings per share of $0.74 against a consensus Street estimate of $0.66, beating the average estimate by $0.08. The company posted a revenue of $4.39 billion compared to an estimation of $4.24 billion.
Is this a Trading Opportunity? Click here for a free Trend Analysis Report
There are currently twenty-six analysts that cover Bristol-Myers Squibb Co stock. Of those twenty-six, fourteen have a Buy rating, ten have a Hold rating and two have a Sell rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $75.73.
A recent analyst activity consisted of Credit Suisse reiterating their Outperform stance on May 9. Credit Suisse increased their price target on BMY from $75 to $79. This corresponds to a 10.44% upside from the last closing price. On the date of report, the stock closed at $71.34.
Societe Generale initiated their coverage on the stock with Sell rating on April 6. On the date of report, the stock closed at $66.54.
Another research firm was Jefferies who reiterated their Hold stance on March 15. Jefferies increased their price target on Bristol-Myers Squibb Co from $63 to $65. This translates to a 9.13% downside from the last closing price. On the date of report, the stock closed at $63.3.
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.